Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Pontiac, MI
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Pontiac, MI
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Roseville, MI
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Roseville, MI
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Kansas City, MO
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Lincoln, NE
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Astoria, NY
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Astoria, NY
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Rosedale, NY
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Rosedale, NY
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Carrboro, NC
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Carrboro, NC
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Wilmington, NC
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Meadville, PA
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Meadville, PA
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Houston, TX
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Houston, TX
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Burlington, VT
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Hampton, VA
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Hampton, VA
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Clinical Research Facility
mi
from
Norfolk, VA
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Research Site
mi
from
Toa Baja,
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Research Site
mi
from
Toa Baja,
Click here to add this to my saved trials
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated:  5/18/2017
Research Site
mi
from
The Bronx, NY
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Status: Enrolling
Updated: 5/18/2017
Research Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
Use of Mobile Technology for Intensive Training in Medication Management
Use of Mobile Technology for Intensive Training in Medication Management
Status: Enrolling
Updated:  5/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Use of Mobile Technology for Intensive Training in Medication Management
Use of Mobile Technology for Intensive Training in Medication Management
Status: Enrolling
Updated: 5/24/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
Clinical Research Facility
mi
from
San Diego, CA
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
Clinical Research Facility
mi
from
Detroit, MI
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
Clinical Research Facility
mi
from
Portland, OR
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated:  5/29/2017
mi
from
Edmonton,
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status: Enrolling
Updated: 5/29/2017
mi
from
Edmonton,
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Brookwood Princeton Baptist
mi
from
Birmingham, AL
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Brookwood Princeton Baptist
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Yavapai Regional Medical Center
mi
from
Prescott, AZ
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Yavapai Regional Medical Center
mi
from
Prescott, AZ
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Kaiser Permanente
mi
from
Baldwin Park, CA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Kaiser Permanente
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Antelope Valley Hospital
mi
from
Lancaster, CA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Antelope Valley Hospital
mi
from
Lancaster, CA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Loma Linda Medical Center
mi
from
Loma Linda, CA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Loma Linda Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Providence Holy Cross Hospital
mi
from
Mission Hills, CA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Providence Holy Cross Hospital
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Medstar Georgetown University Hosiptal
mi
from
Washington, D.C.,
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Medstar Georgetown University Hosiptal
mi
from
Washington, D.C.,
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Tampa General Hospital
mi
from
Tampa, FL
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Augusta University
mi
from
Augusta, GA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Wellstar Atlanta Medical Centre
mi
from
Marietta, GA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Wellstar Atlanta Medical Centre
mi
from
Marietta, GA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Detroit Medical Center Harper Univesity Hospital
mi
from
Detroit, MI
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Detroit Medical Center Harper Univesity Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Englewood Medical Center
mi
from
Englewood, NJ
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Englewood Medical Center
mi
from
Englewood, NJ
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
St. Barnabas
mi
from
Livingston, NJ
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
St. Barnabas
mi
from
Livingston, NJ
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Northwell - North Shore University Hospital
mi
from
Lake Success, NY
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Northwell - North Shore University Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Mt. Sinai /Recanati/Miller Transplantation Institute, Icahn
mi
from
New York, NY
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Mt. Sinai /Recanati/Miller Transplantation Institute, Icahn
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Presbyterian Hospital Novant Health
mi
from
Charlotte, NC
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Presbyterian Hospital Novant Health
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Abington University
mi
from
Abington, PA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Abington University
mi
from
Abington, PA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Hahnemann University Hospital (Rittenhouse)
mi
from
Philadelphia, PA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Hahnemann University Hospital (Rittenhouse)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Medical University of South Carolina
mi
from
Charleston, SC
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials